Physician profile
Clyde E Elliott
NPI 1326058918
$1,422.49
in general payments reported to CMS, 2019-2025
26 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.96 · 2020: $25.36 · 2021: $186 · 2022: $139 · 2023: $311 · 2024: $369 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.13 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $215.30 | 2022-2025 | |
| Pfizer INC. | $210.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $132.51 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.42 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $105.83 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $62.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $54.06 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $53.78 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $49.96 | 2024 | Trelegy Ellipta |
| Abbvie INC. | $44.38 | 2022-2024 | |
| Exact Sciences Corporation | $42.56 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $38.11 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $33.67 | 2019-2021 | |
| Amarin Pharma, INC. | $29.79 | 2021 | |
| Mylan Specialty L.P. | $24.48 | 2024 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $24.37 | 2023 | Auvelity |
| Ironwood Pharmaceuticals, INC | $23.80 | 2023 | Linzess |
| Biohaven Pharmaceuticals, INC. | $22.55 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.91 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.83 | 2025 | Voquezna |
| Insulet Corporation | $16.51 | 2021 | |
| Evoke Pharma, INC. | $16.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.87 | 2022 | |
| Dynavax Technologies Corporation | $15.20 | 2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2022 | |
| Merck Sharp & Dohme LLC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.